Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of
Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels …

Introduction The tau protein plays a central role in Alzheimer's disease (AD), and there is
huge interest in measuring tau in blood and cerebrospinal fluid (CSF). Methods We …

Total tau (t-tau) and phosphorylated tau (p-tau) protein elevations in cerebrospinal fluid
(CFS) are well-established hallmarks of Alzheimer's disease (AD), while the associations of …

One of the hallmarks of Alzheimer's disease is abnormal deposition of tau proteins in the
brain. Although plasma tau has been proposed as a potential biomarker for Alzheimer's …

Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …

Advances in our understanding of tau-mediated neurodegeneration in Alzheimer's disease
(AD) are moving this disease pathway to center stage for the development of biomarkers …

Tau protein aggregation into neurofibrillary tangles in the central nervous system contributes
to the etiology of certain neurodegenerative disorders, including Alzheimer's disease (AD) …

Background We investigated the potential associations between cerebro-spinal fluid (CSF)
levels of phosphorylated tau (P-tau) and total tau (T-tau) with short-term response to …

Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease
mechanisms and alterations of biomarkers during the development of AD. Using cross …

Background Novel phosphorylated-tau (p-tau) blood biomarkers (eg, p-tau181, p-tau217 or
p-tau231), are highly specific for Alzheimer's disease (AD), and can track amyloid-β (Aβ) and …